ArticleCurrent radiopharmaceuticals2021
Meitner-Auger Electron Emitters for Targeted Radionuclide Therapy: Mercury-197m/g and Antimony-119
Article in Current radiopharmaceuticals, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 26 citations in OpenAlex.
- Recycling-compatible electroplating of enriched tin-119 targets for the production of antimony-119 for targeted Auger electron therapy.EJNMMI radiopharmacy and chemistry · 2026Article
- Panitumumab labeled with Auger electron-emittingEJNMMI radiopharmacy and chemistry · 2026Article
- Development and In Vitro Evaluation of [International journal of molecular sciences · 2025Article
- Coordination Chemistry of Emerging Meitner-Auger Electron-Emitting Radiometals for Targeted Radionuclide Therapy.Coordination chemistry reviews · 2025Article
- Quantitative dual-isotope preclinical SPECT/CT imaging and biodistribution of the mercury-197m/g theranostic pair with [EJNMMI radiopharmacy and chemistry · 2025Article
- Developing ether and alcohol based extraction chromatography resins for purification of antimony-119 in nuclear medicine.EJNMMI radiopharmacy and chemistry · 2025Article
- Chemistry of Antimony in Radiopharmaceutical Development: Unlocking the Theranostic Potential of Sb Isotopes.ChemPlusChem · 2024Review
- Sustainable production of radionuclidically pure antimony-119.EJNMMI radiopharmacy and chemistry · 2024Article
- Exploration of commercial cyclen-based chelators for mercury-197 m/g incorporation into theranostic radiopharmaceuticals.Frontiers in chemistry · 2024Article
- The Curies' element: state of the art and perspectives on the use of radium in nuclear medicine.EJNMMI radiopharmacy and chemistry · 2023Review
- Review
- A Third Generation Potentially Bifunctional Trithiol Chelate, ItsInorganic chemistry · 2021Article
- Radiolabelled Cyclic Bisarylmercury: High Chemical and in vivo Stability for Theranostics.ChemMedChem · 2021Article
- Production and radiochemistry of antimony-120m: Efforts toward Auger electron therapy withNuclear medicine and biologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
Targeted Radionuclide Therapies (TRTs) based on Auger emitting radionuclides have the potential to deliver extremely selective therapeutic payloads on the cellular level. However, to fully exploit this potential, suitable radionuclides need to be applied in combination with appropriate delivery systems. In this review, we summarize the state-of-the-art production, purification, chelation and applications of two promising candidates for Targeted Auger Therapy, namely antimony- 119 (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.